All autopsies

// STARTUP COMPARISON

Limeade Israel vs Nexura

Limeade Israel failed in 2021 due to Acquisition Gone Wrong. Nexura failed in 2020 due to Bad Timing. Different causes, different sectors, different eras — but the same simulation outcome.

METRIC🔥 Limeade Israel🔥 Nexura
SectorHealthtechHealthtech
CountryIsraelColombia
Founded20142017
Died20212020
Raised$30M$2M
Peak$30M raised50 clinic partners
Primary CauseAcquisition Gone WrongBad Timing

// WHY EACH FAILED

🔥 Limeade Israel
Acquisition Gone Wrong
Limeade built an employee wellbeing and engagement platform with significant Israeli R&D operations. After raising $30M, Roper Technologies acquired the company in 2021. Post-acquisition the Israeli engineering center was deprioritized as Roper focused on integrating Limeade's US commercial operations. Key Israeli engineers departed and the product development velocity declined significantly.
// LESSON
Israeli R&D centers acquired by US companies need explicit contractual protection of headcount and roadmap independence. Without it, the US commercial integration absorbs all management attention and the R&D center becomes a cost center that gets rationalized.
🔥 Nexura
Bad Timing
Nexura built a telemedicine platform connecting Colombian patients with specialist doctors. It had 50 clinic partnerships when COVID-19 hit in March 2020. The pandemic initially seemed like a tailwind — telemedicine demand exploded. But well-funded competitors including Doctoralia, Doctoranytime, and hospital-backed platforms entered the market simultaneously with COVID-era capital. Nexura could not compete for physician supply or patient acquisition against better-capitalized entrants.
// LESSON
A pandemic tailwind attracts well-funded competition as fast as it creates demand. If you're the underfunded incumbent when the tailwind hits, you get flooded, not lifted. Raise ahead of the macro event, not during it.

// EXPLORE FURTHER